Elicio Therapeutics, Inc. Income (Loss) from Equity Method Investments
Elicio Therapeutics, Inc. (ELTX) reported Income (Loss) from Equity Method Investments of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2023-05-10
- Elicio Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2022-12-31 was $0.00.
- Elicio Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2022-09-30 was $9.00K, a 70.97% decline year-over-year.
- Elicio Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2022-06-30 was $133.00K.
- Elicio Therapeutics, Inc. income (loss) from equity method investments for fiscal 2022 was $151.00K.
- Elicio Therapeutics, Inc. income (loss) from equity method investments for fiscal 2021 was -$96.00K.
- Elicio Therapeutics, Inc. income (loss) from equity method investments for fiscal 2020 was -$71.00K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-05-10 | $9.00K derived: sum of 3 quarters · filed 2023-05-10 | $142.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $9.00K derived: sum of 2 quarters · filed 2023-03-17 | $142.00K derived: sum of 3 quarters · filed 2023-03-17 | $151.00K 10-K · filed 2023-03-17 |
| 2022-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $142.00K derived: sum of 2 quarters · filed 2022-11-14 | $151.00K 10-Q · filed 2022-11-14 | -$21.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $142.00K 10-Q · filed 2022-08-15 | -$30.00K derived: sum of 3 quarters · filed 2023-05-10 | $1.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $9.00K 10-Q · filed 2023-05-10 | -$163.00K derived: sum of 2 quarters · filed 2023-05-10 | -$132.00K derived: sum of 3 quarters · filed 2023-05-10 | -$154.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$141.00K derived: sum of 2 quarters · filed 2023-03-17 | -$163.00K derived: sum of 3 quarters · filed 2023-03-17 | -$96.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $9.00K derived: sum of 2 quarters · filed 2022-11-14 | $76.00K 10-Q · filed 2022-11-14 | -$51.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $45.00K 10-Q · filed 2022-08-15 | -$82.00K derived: sum of 3 quarters · filed 2022-08-15 | -$82.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $67.00K 10-Q · filed 2022-05-16 | -$60.00K derived: sum of 2 quarters · filed 2022-05-16 | -$60.00K derived: sum of 3 quarters · filed 2022-05-16 | -$32.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$127.00K derived: sum of 2 quarters · filed 2022-03-30 | -$99.00K derived: sum of 3 quarters · filed 2022-03-30 | -$71.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $28.00K derived: sum of 2 quarters · filed 2021-11-12 | $56.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $56.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $28.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |